News
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Maintains $38 Price Target
11 Mar 24
News, Price Target, Analyst Ratings
JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price Target
11 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque Psoriasis
11 Mar 24
Biotech, News, Health Care, General
JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $37
28 Feb 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
28 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Protagonist Therapeutics Q4 2023 GAAP EPS $0.44 Beats undefined Estimate, Sales $60.00M Beat $40.00M Estimate
27 Feb 24
Earnings, Earnings Beats, News
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
1 Feb 24
Biotech, Earnings, Large Cap, News, Guidance, Health Care, Contracts, Management, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's After-Market Session
31 Jan 24
Movers
Press releases
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
26 Mar 24
News, Press Releases
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
11 Mar 24
News, Press Releases
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Feb 24
Earnings, Press Releases
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
21 Feb 24
News, Press Releases
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
7 Feb 24
News, Press Releases
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
31 Jan 24
Contracts, Press Releases
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
29 Jan 24
Events, Press Releases